$0.16 EPS Expected for AngioDynamics, Inc. (ANGO)

September 17, 2017 - By Adrian Erickson

 $0.16 EPS Expected for AngioDynamics, Inc. (ANGO)
Investors sentiment increased to 3.16 in 2016 Q4. Its up 0.55, from 2.61 in 2016Q3. It increased, as 8 investors sold AngioDynamics, Inc. shares while 23 reduced holdings. 32 funds opened positions while 66 raised stakes. 61.14 million shares or 119.62% more from 27.84 million shares in 2016Q3 were reported.
179,409 were accumulated by American Century Companies Incorporated. Swiss Bancshares accumulated 55,800 shares. State Board Of Administration Of Florida Retirement Sys holds 0% or 35,168 shares. Mutual Of America Capital Limited Liability Corp has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). 197,463 were accumulated by Martingale Asset Mngmt L P. Prelude Mgmt Ltd Limited Liability Company holds 0.07% or 35,924 shares. White Pine Limited Liability Corp stated it has 0.21% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Schwab Charles Invest Management Incorporated has 140,276 shares. Legal And General Pcl has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). New York State Common Retirement Fund invested in 233,355 shares. Gamco Invsts Et Al stated it has 0.01% of its portfolio in AngioDynamics, Inc. (NASDAQ:ANGO). Spark Inv Management Ltd Liability Corp holds 138,500 shares or 0.19% of its portfolio. New York-based Tiaa Cref Inv Mngmt Llc has invested 0% in AngioDynamics, Inc. (NASDAQ:ANGO). Stevens Cap L P has invested 0.01% in AngioDynamics, Inc. (NASDAQ:ANGO). Northwestern Mutual Wealth Management invested in 0% or 17 shares.

Wall Street await AngioDynamics, Inc. (NASDAQ:ANGO) to release earnings on October, 4. Analysts forecast earnings per share of $0.16, down exactly $0.01 or 5.88 % from 2014’s $0.17 EPS. The expected ANGO’s profit could reach $5.85M giving the stock 28.06 P/E in the case that $0.16 earnings per share is reported. After posting $0.19 EPS for the previous quarter, AngioDynamics, Inc.’s analysts now forecast -15.79 % negative EPS growth. The stock increased 0.06% or $0.01 on September 15, reaching $17.96. About 481,998 shares traded or 126.45% up from the average. AngioDynamics, Inc. (NASDAQ:ANGO) has risen 31.47% since September 17, 2016 and is uptrending. It has outperformed by 14.77% the S&P500.

AngioDynamics, Inc. (NASDAQ:ANGO) Ratings Coverage

Among 7 analysts covering AngioDynamics (NASDAQ:ANGO), 1 have Buy rating, 0 Sell and 6 Hold. Therefore 14% are positive. AngioDynamics had 16 analyst reports since July 24, 2015 according to SRatingsIntel. Canaccord Genuity maintained AngioDynamics, Inc. (NASDAQ:ANGO) rating on Wednesday, May 31. Canaccord Genuity has “Hold” rating and $16.5000 target. The stock has “Sell” rating by Zacks on Monday, August 31. The rating was maintained by Canaccord Genuity with “Hold” on Sunday, August 6. The firm earned “Overweight” rating on Friday, July 24 by KeyBanc Capital Markets. The rating was reinitiated by Piper Jaffray on Friday, April 8 with “Neutral”. Canaccord Genuity maintained the shares of ANGO in report on Monday, July 10 with “Hold” rating. Cantor Fitzgerald initiated AngioDynamics, Inc. (NASDAQ:ANGO) on Friday, November 4 with “Buy” rating. As per Thursday, August 24, the company rating was maintained by KeyBanc Capital Markets. Raymond James downgraded the shares of ANGO in report on Tuesday, November 10 to “Mkt Perform” rating. The rating was maintained by Canaccord Genuity on Tuesday, July 18 with “Hold”.

AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The company has market cap of $657.10 million. The Company’s devices are used in minimally invasive, image-guided procedures. It has a 136.08 P/E ratio. The Firm offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery.

More news for AngioDynamics, Inc. (NASDAQ:ANGO) were recently published by: Globenewswire.com, which released: “AngioDynamics to Report Fiscal 2018 First Quarter Financial Results” on September 14, 2017. Globenewswire.com‘s article titled: “Outcomes in a Nurse-Led Peripherally Inserted Central Catheter Program: A …” and published on September 14, 2017 is yet another important article.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: